title: [Two cases of postoperative recurrence of gastric GIST treated by imatinib].
abstract: We report two cases of postoperative recurrence of gastrointestinal stromal tumor (GIST) treated by the tyrosine kinase inhibitor imatinib mesylate (IM), and discuss some important items. Case 1: This 63-year-old Japanese man received a partial gastrectomy for leiomyosarcoma in 1993. Partial hepatectomy and proximal gastrectomy were performed for liver metastasis and local recurrence in 2001. However, 5 months after surgery, a CT scan showed multiple tumors in the liver, lung and thyroid. The patient was treated with 300 mg of IM once daily with transient grade 2 neutropenia and intestinal bleeding. Though the response to treatment was SD-PR initially, a CT scan 15 months after initial treatment demonstrated the regrowth of the tumor in his liver. Case 2: A 63-year-old Japanese woman was treated with 200 mg of IM once daily for multiple liver metastases after gastrectomy for GIST with grade 3 neutropenia and edema of legs. The response to treatment was SD, and continued for 12 months. IM is the treatment of choice for unresectable recurrence of GIST. However, some problems remained. Both basic and clinical research is necessary to increase the therapeutic efficacy of IM.
authors.affiliation: Dept of Surgery, Hamamatsu University School of Medicine.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Kikuchi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Konn
authors.forename: Kinji
authors.initials: K
authors.lastname: Kamiya
authors.forename: Megumi
authors.initials: M
authors.lastname: Baba
authors.forename: Manabu
authors.initials: M
authors.lastname: Ohta
authors.forename: Kenji
authors.initials: K
authors.lastname: Kondo
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hiramatsu
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Tanaka
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Sugimura
authors.forename: Manabu
authors.initials: M
authors.lastname: Ohashi
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kanda
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005743:Gastrectomy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013964:Thyroid Neoplasms / Q000556:secondary
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases